Nutrition Rounds: Recent Advances in the Treatment of Obesity
This activity reviews current options for the pharmacological treatment of obesity and describe the concomitant role of diet counseling and lifestyle interventions with new obesity therapies.
Content delves into the biological basis of obesity including the role of hormones on appetite and energy regulation, metabolic adaptation to weight loss, and cardiometabolic risk factors.
Special ASN Member Benefit - 50% Off for Members!
ASN members receive this course for 50% off. Login now to get the $7.50 special member rate. If you do not see the member rate displayed for you after logging in, please contact discover@nutrition.org.
Not an ASN member? Click here to join ASN to receive member rates on all DiscoverNUTRITION products!
Speakers
John Buse, MD, PhD
Verne S. Caviness Distinguished Professor; Chief, Division of Endocrinology
University of North Carolina School of Medicine
Ania Jastreboff, MD, PhD
Associate Professor of Medicine, Endocrinology & Metabolism
Yale University School of Medicine
Richard Kahn, PhD
Department of Medicine
University of North Carolina, Chapel Hill
Learning Objectives
- Communicate the importance of treating obesity as a disease for optimal patient outcomes
- Review the biological basis of obesity including the role of hormones on appetite and energy regulation, metabolic adaptation to weight loss, and cardiometabolic risk factors
- Explain current options for the pharmacological treatment of obesity, including safety and efficacy
- Describe the concomitant role of diet counseling and lifestyle interventions with new obesity therapies
Keywords
- Overweight and obesity
- Weight loss
- Diet
- Lifestyle interventions
- GLP-1 analogue
- Diabetes
- Prediabetes
Target Audience
- Researchers
- Physicians
- Dietitians
- Physician Assistants and Nurse Practitioners
- Academic Faculty
- Health Educators
- Behavioral Specialists
- Nurses
- Pharmacists
- Wellness Professionals
- Undergraduate/Graduate Students/Postdoctoral Fellows
- Medical Students and Residents
Performance Indicators for Registered Dietitians
- 4.2.6 Integrates relevant information with previous learning, experience, professional knowledge, and current practice models.
- 10.3.4 Selects interventions intended to resolve or improve nutrition diagnose.
- 10.4.4 Considers client/patient factors, nutritional impacts, indications, side effects, contraindications, benefits, risks, alternatives and foundational sciences when prescribing, recommending or administering nutrition-related drug therapy.
- 10.4.5 Implements, initiates, or modifies nutrition-related pharmacotherapy orders that address client/patient needs.
This activity includes the following presentations:
Anti-obesity Pharmacotherapy: The Future Is Now!
Ania Jastreboff, MD, PhD
Associate Professor of Medicine, Endocrinology & Metabolism
Yale University School of Medicine
GLP-1 Receptor Agonists for Obesity: Personal and Professional Perspectives
John Buse, MD, PhD
Verne S. Caviness Distinguished Professor; Chief, Division of Endocrinology
University of North Carolina School of Medicine
Panel Discussion - Recent Advances in the Treatment of Obesity
John Buse, MD, PhD
Verne S. Caviness Distinguished Professor; Chief, Division of Endocrinology
University of North Carolina School of Medicine
Ania Jastreboff, MD, PhD
Associate Professor of Medicine, Endocrinology & Metabolism
Yale University School of Medicine
Richard Kahn, PhD
Department of Medicine
University of North Carolina, Chapel Hill
Disclosure Policy
The American Society for Nutrition supports fair and unbiased participation of individuals in its education activities. Any real or potential conflicts of interest must be identified and managed. All relevant financial relationships with commercial interests that directly impact and/or might conflict with ASN activities must be disclosed, or disclosure that no relevant financial relationships exist must be documented. Other relationships that could cause private interests to conflict with professional interests must also be disclosed. This policy is intended to openly identify any potential conflict so that participants in an education activity are able to form their own judgments about the presentation. In addition, disclosure must be made of presentations on drugs or devices or uses of drugs or devices that have not been approved by the Food and Drug Administration.
Speakers
John Buse, MD, PhD, Verne S. Caviness Distinguished Professor; Chief, Division of Endocrinology, University of North Carolina School of Medicine
Disclosures: Grant/Research Support: Dexcom, NovaTarg, Novo Nordisk, Sanofi, Tolerion, vTv Therapeutics; Consultant: Alkahest, Altimmune, Anji, AstraZeneca, Bayer, Biomea Fusion Inc, Boehringer-Ingelheim, CeQur, Cirius Therapeutics Inc, Eli Lilly, GentiBio, Glycadia, Glyscend, Janssen, MannKind, Mellitus Health, Moderna, Novo Nordisk, Pendulum Therapeutics, Praetego, Stability Health, Valo, Zealand Pharma; Stock: Glyscend, Mellitus Health, Pendulum Therapeutics, PhaseBio, Praetego, Stability Health
All of the relevant financial relationships listed for this individual have been mitigated.
Ania Jastreboff, MD, PhD, Associate Professor of Medicine, Endocrinology & Metabolism, Yale University School of Medicine
Disclosures: Consultant: Boehringer Ingelheim, Eli Lilly, Intellihealth, Novo Nordisk, Novo Nordisk AS, Pfizer, Rhythm Pharmaceuticals, Scholar Rock, WWF International; Grant/Research Support: Eli Lilly, Novo Nordisk, Rhythm Pharmaceuticals
All of the relevant financial relationships listed for this individual have been mitigated.
Richard Kahn, PhD, Department of Medicine, University of North Carolina, Chapel Hill
Disclosure(s): Abbott: Consultant: Abbott
All of the relevant financial relationships listed for this individual have been mitigated.
Planners
Sahar Ajabshir, PhD, Florida International University
No relevant financial relationship(s) with ineligible companies to disclose.
Ann Anderson-Berry, MD, PhD, University of Nebraska Medical
Disclosures: Center Data and Safety Monitoring Committee: Pfizer
All of the relevant financial relationships listed for this individual have been mitigated.
Cora Best, PhD, MHS, RDN, University of Washington School of Medicine
No relevant financial relationship(s) with ineligible companies to disclose.
Yanbin Dong, PhD, Augusta University
No relevant financial relationship(s) with ineligible companies to disclose.
Roschelle Heuberger, PhD, RD, Central Michigan University
No relevant financial relationship(s) with ineligible companies to disclose.
David Seres, MD, ScM, PNS, FASPEN, Columbia University
Disclosures: Consultant: Community Surgical, Fresenius-Kabi
All of the relevant financial relationships listed for this individual have been mitigated.
Christy Tangney, PhD, MS, Rush Medical College
No relevant financial relationship(s) with ineligible companies to disclose.
Staff
Michelle Crispino, CAE, DES, American Society for Nutrition
No relevant financial relationship(s) with ineligible companies to disclose.
Gwen Twillman, American Society for Nutrition
No relevant financial relationship(s) with ineligible companies to disclose.
Accreditation Statement
ASN (Provider #NS010) is accredited and approved by the Commission on Dietetic Registration (CDR) as a provider of Continuing Professional Education (CPE) programs for Registered Dietitians.
Credit Designation
Dietitians/Dietetic Technicians
ASN (Provider #NS010) is accredited and approved by the Commission on Dietetic Registration (CDR) as a provider of Continuing Professional Education (CPE) programs for Registered Dietitians. ASN designates this activity for a maximum of 1.5 CPE credits.
Activity Type: Recorded pre-approved CPE Activity: 175 Lectures/Webinars
Activity Number: 172653
CPE Level 2
Performance Indicators/Learning Objectives
- 4.2.6 Integrates relevant information with previous learning, experience, professional knowledge, and current practice models.
- 10.3.4 Selects interventions intended to resolve or improve nutrition diagnose.
- 10.4.4 Considers client/patient factors, nutritional impacts, indications, side effects, contraindications, benefits, risks, alternatives and foundational sciences when prescribing, recommending or administering nutrition-related drug therapy.
- 10.4.5 Implements, initiates, or modifies nutrition-related pharmacotherapy orders that address client/patient needs.
Other Learners
Learners who take this course will receive a Certificate of Attendance. This certificate does not confer continuing education credit and indicates the course has been completed.
Available Credit
- 1.50 Attendance
Learners are eligible to download a Certificate of Attendance upon activity completion. A Certificate of Attendance confirms the learner has completed the activity and does not confer any continuing education credit to the learner from ASN.
- 1.50 CPE for Registered Dietitians
ASN (Provider #NS010) is accredited and approved by the Commission on Dietetic Registration (CDR) as a provider of Continuing Professional Education (CPE) programs for Registered Dietitians.
ASN designates this activity for a maximum of 1.50 CPE credits.
Price
Special ASN Member Benefit - 50% Off for Members!
ASN members receive this course for 50% off. Login now to get the $7.50 special member rate. If you do not see the member rate displayed for you after logging in, please contact discover@nutrition.org.
Not an ASN member? Click here to join ASN to receive member rates on all DiscoverNUTRITION products!